Xarelto® - (rivaroxaban) - The Most Broadly Indicated NOAChttp://portalrankings.com/info/xarelto.com
Information about Xarelto (Rivaroxaban), stroke prevention in atrial fibrillation, treatment and prevention of VTE (DVT/PE) and Secondary Prevention after ACS
- Updated On (Date): 2017-Jan-12
- Expiration time: 2019-Jan-16
- Website Registered On (Date): 2002-Jan-16